Approved for To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. 12.1 Mechanism of Action Iberdomide is a cereblon-modulating protein degrader that binds to cereblon, a substrate recognition component of an E3…
Loading full data from Know Your Drugs Institute…